China has broken ground on what developers say is the country’s first production line for AI-assisted personalised tumour vaccines, raising hopes for millions of new cancer patients every year – a disease that ranks as the nation’s second-leading cause of death. By October, Beijing-based Likang Life Sciences is expected to complete a new drug research and manufacturing centre in the Beijing Economic and Technological Development Zone, with a total investment of about 110 million yuan (US$16.1...
UPVOTERS
Community appreciation
See who found this content valuable and showed their support.
TOPICS
Explore the same topics
Discover more content from the topics this post is mapped to.
Keep browsing
Explore more from this topic
Dive into the full feed of curated posts covering Automotive News & Trends.
Discussion
Take the lead—comment now
Lead the way—your insights can inspire others.